Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引：3

作者：

Sznol, M. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Hogg, D. ^{[3
]}

Atkins, M. ^{[4
]}

Wolter, P. ^{[5
]}

Guidoboni, M. ^{[6
]}

Lebbe, C. ^{[7
]}

Kirkwood, J. ^{[8
]}

Schachter, J. ^{[9
]}

Daniels, G. ^{[10
]}

Hassel, J. ^{[11
]}

Cebon, J. ^{[12
]}

Gerritsen, W. ^{[13
]}

Atkinson, V. ^{[14
,15
]}

Thomas, L. ^{[16
]}

McCaffrey, J. ^{[17
]}

Power, D. ^{[18
]}

Jiang, J. ^{[19
]}

Hodi, F. S. ^{[20
]}

Wolchok, J. ^{[21
]}

机构：

[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy

[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA

[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium

[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy

[7] Hop St Louis, Dermatol, Paris, France

[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA

[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA

[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany

[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia

[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands

[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia

[15] Princess Alexandra Hosp, Greenslopes, Australia

[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France

[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland

[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland

[19] BMS, Oncol, Princeton, NJ USA

[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA

[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1123P

引用

页数：1

共 50 条

[21] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067) [J].

Wolchok, Jedd D. ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Rutkowski, Piotr ;

Grob, Jean Jacques ;

Cowey, Charles Lance ;

Lao, Christopher D. ;

Schadendorf, Dirk ;

Ferrucci, Pier Francesco ;

Smylie, Michael ;

Dummer, Reinhard ;

Hill, Andrew Graham ;

Haanen, John B. A. G. ;

Maio, Michele ;

McArthur, Grant A. ;

Yang, Arvin ;

Rollin, Linda ;

Horak, Christine E. ;

Larkin, James M. G. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)

[22] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040 [J].

He, Aiwu Ruth ;

Yau, Thomas ;

Hsu, Chiun ;

Kang, Yoon-Koo ;

Kim, Tae-You ;

Santoro, Armando ;

Sangro, Bruno ;

Melero, Ignacio ;

Kudo, Masatoshi ;

Hou, Ming-Mo ;

Matilla, Ana ;

Tovoli, Francesco ;

Knox, Jennifer J. ;

El-Rayes, Bassel F. ;

Acosta-Rivera, Mirelis ;

Neely, Jaclyn ;

Shen, Yun ;

Tschaika, Marina ;

El-Khoueiry, Anthony B. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

[23] Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) [J].

Postow, Michael ;

Chesney, Jason ;

Pavlick, Anna ;

Robert, Caroline ;

Grossmann, Kenneth ;

McDermott, David ;

Linette, Gerald ;

Meyer, Nicolas ;

Giguere, Jeffrey ;

Agarwala, Sanjiv ;

Shaheen, Montaser ;

Ernstoff, Marc ;

Minor, David ;

Salama, April ;

Taylor, Matthew ;

Ott, Patrick ;

Jiang, Joel ;

Horak, Christine ;

Gagnier, Paul ;

Wolchok, Jedd ;

Hodi, F. Stephen .

CANCER RESEARCH, 2016, 76

[24] Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). [J].

Wolchok, Jedd D. ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Rutkowski, Piotr ;

Grob, Jean Jacques ;

Cowey, C. Lance ;

Lao, Christopher ;

Schadendorf, Dirk ;

Ferrucci, Pier Francesco ;

Smylie, Michael ;

Dummer, Reinhard ;

Hill, Andrew ;

Haanen, John B. A. G. ;

Maio, Michele ;

McArthur, Grant A. ;

Walker, Dana ;

Jiang, Joel ;

Horak, Christine E. ;

Larkin, James M. G. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[25] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. [J].

Yau, Thomas ;

Kang, Yoon-Koo ;

Kim, Tae-You ;

El-Khoueiry, Anthony B. ;

Santoro, Armando ;

Sangro, Bruno ;

Melero, Ignacio ;

Kudo, Masatoshi ;

Hou, Ming-Mo ;

Matilla, Ana ;

Tovoli, Francesco ;

Knox, Jennifer J. ;

He, Aiwu Ruth ;

El-Rayes, Bassel F. ;

Acosta-Rivera, Mirelis ;

Neely, Jaclyn ;

Shen, Yun ;

Baccan, Carlos ;

Dela Cruz, Christine Marie ;

Hsu, Chiun .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[26] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO [J].

Schadendorf, D. ;

Ugurel, S. ;

Eigentler, T. ;

Mohr, P. ;

Wei-Chenthal, M. ;

Gebhardt, C. ;

Goppner, D. ;

Haferkamp, S. ;

Herbst, R. ;

Kahler, K. ;

Kreuter, A. ;

Meier, F. ;

Pfohler, C. ;

Sachse, M. M. ;

Sickmann, T. ;

Terheyden, P. ;

Ulrich, J. ;

Utikal, J. S. ;

Grimmel-Mann, I. ;

Gutzmer, R. .

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 :16-17

[27] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). [J].

Tawbi, Hussein Abdul-Hassan ;

Forsyth, Peter A. J. ;

Hodi, F. Stephen ;

Lao, Christopher D. ;

Moschos, Stergios J. ;

Hamid, Omid ;

Atkins, Michael B. ;

Lewis, Karl D. ;

Thomas, Reena Parada ;

Glaspy, John A. ;

Jang, Sekwon ;

Algazi, Alain Patrick ;

Khushalani, Nikhil I. ;

Postow, Michael A. ;

Pavlick, Anna C. ;

Ernstoff, Marc S. ;

Reardon, David A. ;

Balogh, Agnes ;

Rizzo, Jasmine I. ;

Margolin, Kim Allyson .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[28] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis [J].

Long, G. V. ;

Larkin, J. ;

Ascierto, P. A. ;

Hodi, F. S. ;

Rutkowski, P. ;

Sileni, V. ;

Hassel, J. ;

Lebbe, C. ;

Pavlick, A. C. ;

Wagstaff, J. ;

Schadendorf, D. ;

Dummer, R. ;

Hogg, D. ;

Haanen, J. B. A. G. ;

Corrie, P. ;

Hoeller, C. ;

Horak, C. ;

Wolchok, J. ;

Robert, C. .

ANNALS OF ONCOLOGY, 2016, 27

[29] EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067) [J].

Larkin, James ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Grob, Jean-Jacques ;

Cowey, C. Lance ;

Lao, Christopher D. ;

Wagstaff, John ;

Hogg, David ;

Hill, Andrew ;

Carlino, Matteo S. ;

Wolter, Pascal ;

Lebbe, Celeste ;

Schachter, Jacob ;

Thomas, Luc ;

Hassal, Jessica C. ;

Lorigan, Paul ;

Walker, Dana ;

Jiang, Joel ;

Hodi, F. Stephen ;

Wolchok, Jedd D. .

Asia-Pacific Journal of Clinical Oncology, 2015, 11 :126-126

[30] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067) [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J. J. ;

Cowey, C. L. ;

Lao, C. D. ;

Wagstaff, J. ;

Hogg, D. ;

Hill, A. ;

Carlino, M. S. ;

Wolter, P. ;

Lebbe, C. ;

Schachter, J. ;

Thomas, L. ;

Hassel, J. C. ;

Lorigan, P. ;

Walker, D. ;

Jiang, J. ;

Hodi, F. S. ;

Wolchok, J. D. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S664-S665

← 1 2 3 4 5 →